Page 119 - 2020_11-Haematologica-web

Prognostic impact of CLL stereotyped subsets
17. Bomben R, Dal Bo M, Capello D, et al. Comprehensive characterization of IGHV3- 21-expressing B-cell chronic lymphocytic leukemia: an Italian multicenter study. Blood. 2007;109(7):2989-2998.
18. Jeromin S, Haferlach C, Dicker F, et al. Differences in prognosis of stereotyped IGHV3-21 chronic lymphocytic leukaemia according to additional molecular and cyto- genetic aberrations. Leukemia. 2016; 30(11):2251-2253.
19. Xochelli A, Baliakas P, Kavakiotis I, et al. Chronic Lymphocytic Leukemia with Mutated IGHV4-34 Receptors: Shared and Distinct Immunogenetic Features and Clinical Outcomes. Clin Cancer Res. 2017; 23(17):5292-5301.
20. Gounari M, Ntoufa S, Apollonio B, et al. Excessive antigen reactivity may underlie the clinical aggressiveness of chronic lym- phocytic leukemia stereotyped subset #8. Blood. 2015;125(23):3580-3587.
21. Hoechstetter MA, Busch R, Eichhorst B, et al. Early, risk-adapted treatment with flu- darabine in Binet stage A chronic lympho- cytic leukemia patients: results of the CLL1 trial of the German CLL study group. Leukemia. 2017;31(12):2833-2837.
22. Hallek M, Fischer K, Fingerle-Rowson G, et al. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet. 2010;376(9747):1164-1174.
23. Fischer K, Bahlo J, Fink AM, et al. Long-term remissions after FCR chemoimmunothera- py in previously untreated patients with CLL: updated results of the CLL8 trial. Blood. 2016;127(2):208-215.
24. Eichhorst B, Fink A-M, Bahlo J, et al. First-
line chemoimmunotherapy with bendamus- tine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open- label, randomised, phase 3, non-inferiority trial. Lancet Oncol. 2016;17(7):928-942.
25. Goede V, Fischer K, Busch R, et al. Obinutuzumab plus chlorambucil in patients with CLL and coexisting condi- tions. N Engl J Med. 2014;370(12):1101- 1110.
26. Döhner H, Stilgenbauer S, Benner A, et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med. 2000;343(26):1910-1916.
27. Kröber A, Seiler T, Benner A, et al. V(H) mutation status, CD38 expression level, genomic aberrations, and survival in chronic lymphocytic leukemia. Blood. 2002; 100(4):1410-1416.
28. Thunberg U, Johnson A, Roos G, et al. CD38 expression is a poor predictor for VH gene mutational status and prognosis in chronic lymphocytic leukemia. Blood. 2001; 97(6):1892-1894.
29. Strefford JC, Sutton L-A, Baliakas P, et al. Distinct patterns of novel gene mutations in poor-prognostic stereotyped subsets of chronic lymphocytic leukemia: the case of SF3B1 and subset #2. Leukemia. 2013; 27(11):2196-2199.
30. Hallek M, Wanders L, Ostwald M, et al. Serum beta(2)-microglobulin and serum thymidine kinase are independent predic- tors of progression-free survival in chronic lymphocytic leukemia and immunocytoma. Leuk Lymphoma. 1996;22(5-6):439-447.
31. Kaplan EL, Meier P. Nonparametric estima- tion from incomplete observations. J. Amer.
Statist. Assn. 1958;53(282):457-481.
32. Tobin G, Thunberg U, Johnson A, et al. Somatically mutated Ig V(H)3-21 genes char- acterize a new subset of chronic lymphocyt-
ic leukemia. Blood. 2002;99(6):2262-2264. 33. Thorsélius M, Kröber A, Murray F, et al. Strikingly homologous immunoglobulin gene rearrangements and poor outcome in VH3-21-using chronic lymphocytic leukemia patients independent of geograph- ic origin and mutational status. Blood.
2006;107(7):2889-2894.
34. Ghia EM, Jain S, Widhopf GF, et al. Use of
IGHV3-21 in chronic lymphocytic leukemia is associated with high-risk disease and reflects antigen-driven, post-germinal center leukemogenic selection. Blood. 2008; 111(10):5101-5108.
35. Rossi D, Spina V, Bomben R, et al. Association between molecular lesions and specific B-cell receptor subsets in chronic lymphocytic leukemia. Blood. 2013;121(24): 4902-4905.
36. Rossi D, Spina V, Cerri M, et al. Stereotyped B-cell receptor is an independent risk factor of chronic lymphocytic leukemia transfor- mation to Richter syndrome. Clin Cancer Res. 2009;15(13):4415-4422.
37. Kipps TJ, Fraser G, Coutre S, et al. Unmutated IGHV is not an adverse predic- tor of outcome to therapy with ibrutinib in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). Cancer Res 2017;77(13 Suppl):abstract CT158.
38. Wierda WG, Byrd JC, Abramson JS, et al. NCCN guidelines insights: chronic lympho- cytic leukemia/small lymphocytic lym- phoma, version 2.2019. J Natl Compr Canc Netw. 2019;17(1):12-20.
haematologica | 2020; 105(11)
2607